Biogen and Eisai win Japanese approval for Leqembi injection pen
Biogen ($BIIB) and Eisai received Japanese approval for Leqembi Pen, a subcutaneous formulation of their treatment for early Alzheimer’s disease. The regimen uses two pens totaling 500 milligrams once weekly, offering an alternative to intravenous treatment every two weeks. The companies expect the format to reduce the burden of repeated hospital visits. At-home administration still requires the product’s inclusion on the designated injectable-drug list, followed by appropriate physician assessm
0